Financial Daily from THE HINDU group of publications
Friday, May 05, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Corporate - Corporate Disputes


Euphoria over cholesterol drug Zocor misplaced, say analysts

P.T. Jyothi Datta
Deeptha Rajkumar

Many players in the fray; much hinges on USFDA decision

Mumbai , May 4

It may be too early to celebrate the prospects held out by cholesterol-lowering drug Zocor for Indian generic drug companies like Ranbaxy and Dr Reddy's, say analysts. The reason is that Zocor's exclusivity-related issues remain unresolved by the United States Food and Drug Administration (USFDA).

Despite a recent ruling from the US federal court, perceived to be favourable to Indian drug majors, uncertainty looms over Zocor's future, with the court reverting the exclusivity issue to the USFDA, points out an analyst. Zocor is a $4.5 billion drug.

Earlier this week, a federal court in the US had ruled that the USFDA had unfairly denied Israeli drug company Teva's petition to exclusively market generic forms of Merck & Co's cholesterol drug Simvastatin sold under the brand name Zocor. The court also sent the issue back to the USFDA and herein lies the fate of the Indian drug companies, an analyst said.

If the USFDA sticks to its original position and denies Teva and Ranbaxy 180-days' exclusivity, then the patent on Zocor expires on June 23.

Subsequently, a host of generic companies can make Simvastatin, including Teva, Ranbaxy, Dr Reddy's and Aurobindo, besides other drug companies like Biocon waiting in the wings.

The pie gets divided between several companies and, as witnessed in the case of other drugs going off patent, the price erosion can be up to 95 per cent, he said.

In the event that Teva gets exclusivity on four strengths (5 mg, 10 mg, 20 mg and 40 mg) of Simvastatin and Ranbaxy gets exclusivity on 80 mg of the same drug (estimated to be only $ 500 million of the total Simvastatin market), Merck still has its finger in the pie.

It has authorised Dr Reddy's to make and sell Simvastatin, and will get a share of the sales proceeds, he observed.

Market euphoria

A JM Morgan Stanley report said that an approval for Ranbaxy translates into a 15 per cent contribution to the company's 2006 earnings.

However this could be adversely impacted if there is a delay.

Either way, the euphoria earlier this week in the stock markets over the court ruling was misplaced as there are several players in the market and, more important, much still hangs on the decision of the USFDA, he pointed out.

Dr Reddy's closed on the BSE at Rs 1,645.95, down 0.34 per cent from its previous close.

The stock has appreciated by almost 14.7 per cent, week on week. Ranbaxy ended the day at Rs 509.55, down 0.93 per cent from its previous close.

The counter reflected an 8 per cent gain, week on week.

More Stories on : Pharmaceuticals | Corporate Disputes | IPR | Health | Ranbaxy Laboratories Ltd | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
DoT's spectrum policy gets COAI support


Spectrum service to help lawyers
`India will be developed nation in less than 14 yrs'
Euphoria over cholesterol drug Zocor misplaced, say analysts
Captive power units spell money for big corporates
35 cos vie for `ultra mega' plants
Raymond Q4 net profit dips 22 pc
3i Info has on its radar 5 or 6 small product firms
Yahoo keen on big slice of action in India
Banks' g-sec holdings hit 20-year low
Bharti charts Rs 200-crore primary education project
IT cos wake up to work-from-hometown concept
JP Morgan downgrades Indian stocks as `Bharat PE achieved'
DoT demands foolproof verification of mobile users
Broadband penetration still low: Report
Regulator favours benign tax regime for pensions



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line